NCT05900531View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 21, 2022

Primary Completion Date

May 3, 2023

Study Completion Date

May 31, 2023

Conditions
Obesity
Interventions
DRUG

K-757

administered orally

DRUG

K-757 and open-label sitagliptin

both administered orally

DRUG

Matching placebo to K-757

administered orally

DRUG

Matching placebo to K-757 and matching placebo to K-833

both administered orally

DRUG

K-757 and K-833

both administered orally

DRUG

Matching placebo to K-757, open-label sitagliptin

both administered orally

Trial Locations (1)

91911

ProSciento, Inc., Chula Vista

Sponsors

Lead Sponsor

Kallyope Inc.
All Listed Sponsors
lead

Kallyope Inc.

INDUSTRY